Copper cu-64 dotatate - Generic Drug Details

What are the generic sources for copper cu-64 dotatate and what is the scope of freedom to operate?

Copper cu-64 dotatate is the generic ingredient in one branded drug marketed by Curium and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Copper cu-64 dotatate has nineteen patent family members in twelve countries.

One supplier is listed for this compound.

Summary for copper cu-64 dotatate

International Patents:	19
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	3
DailyMed Link:	copper cu-64 dotatate at DailyMed

Recent Clinical Trials for copper cu-64 dotatate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Hospital, Basel, Switzerland	PHASE1
Vanderbilt-Ingram Cancer Center	PHASE4
National Cancer Institute (NCI)	Phase 1

See all copper cu-64 dotatate clinical trials

Pharmacology for copper cu-64 dotatate

Drug Class	Radioactive Diagnostic Agent
Mechanism of Action	Positron Emitting Activity

US Patents and Regulatory Information for copper cu-64 dotatate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Curium	DETECTNET	copper cu-64 dotatate	SOLUTION;INTRAVENOUS	213227-001	Sep 3, 2020		RX	Yes	Yes
Curium	DETECTNET	copper cu-64 dotatate	SOLUTION;INTRAVENOUS	213227-001	Sep 3, 2020		RX	Yes	Yes			Y
Curium	DETECTNET	copper cu-64 dotatate	SOLUTION;INTRAVENOUS	213227-001	Sep 3, 2020		RX	Yes	Yes
Curium	DETECTNET	copper cu-64 dotatate	SOLUTION;INTRAVENOUS	213227-001	Sep 3, 2020		RX	Yes	Yes
Curium	DETECTNET	copper cu-64 dotatate	SOLUTION;INTRAVENOUS	213227-001	Sep 3, 2020		RX	Yes	Yes

International Patents for copper cu-64 dotatate

Country	Patent Number	Title	Estimated Expiration
China	116583527
Japan	2023539893
Poland	2750717
Spain	2732823
Denmark	2750717
World Intellectual Property Organization (WIPO)	2022051684
Mexico	2023002614

Market Overview and Financial Outlook for Copper Cu-64 DOTATATE

Last updated: February 16, 2026

Copper Cu-64 DOTATATE is a radiopharmaceutical used in diagnostic imaging for neuroendocrine tumors. It is part of the peptide receptor radionuclide therapy (PRRT) class, pending broader adoption for diagnostic purposes. The compound is distinguished by its use of copper-64, a radionuclide with favorable physical properties for PET imaging.

Current Market Position

As of 2023, Copper Cu-64 DOTATATE remains in early commercial stages with limited market penetration, primarily driven by ongoing clinical validation and regulatory approvals. Its main competitors include Ga-68 DOTATATE and F-18 SSTR PET scans, which have broader adoption based on prior clinical data and established supply chains.

Regulatory Milestones

• FDA Approval: Not yet approved for widespread clinical use as a diagnostic agent.
• EMA Status: Pending submissions for approval in European markets.
• ClinicalTrials: Several phase 2 and phase 3 trials ongoing to establish efficacy, with completion expected between 2024 and 2026.

Market Drivers

• Increasing incidence of neuroendocrine tumors (NETs).
• Growing adoption of PET imaging for precise tumor localization.
• Limitations of existing radiotracers (e.g., production complexity, short half-life of Gallium-68).

Market Challenges

• Regulatory delays.
• Competition from established tracers.
• Manufacturing and supply chain complexities related to copper-64 production.

Projected Market Size and Growth

Year	Estimated Global Market (USD billions)	Growth Rate (CAGR)	Source/Note
2023	0.2	--	Early-stage market, limited adoption
2025	0.4	20%	Growth driven by regulatory approvals and clinical validation
2030	0.9	18%	Potential for increased adoption as data embeds

Revenue and Investment Outlook

• Short-Term (2023-2025):

  • Revenue: Under USD 50 million, primarily from early sales to research institutions.
  • Investment: Focused on manufacturing scale-up, clinical trials, and regulatory submission costs.

• Mid to Long-Term (2026-2030):

  • Revenue could exceed USD 500 million if approved and adopted broadly.
  • Companies like Curium, Novartis, or small biotech players could capture segments through partnerships or direct marketing.

Financial Risks and Opportunities

Risks:

• Delays in regulatory approval.
• Competition with mature, off-label agents.
• Supply chain disruptions, especially copper-64 production constraints.

Opportunities:

• Superior imaging resolution and half-life properties.
• Expanding clinical applications beyond neuroendocrine tumors.
• Partnerships with diagnostic imaging providers.

---

Key Takeaways

• Copper Cu-64 DOTATATE remains in early commercialization, with limited revenue and significant potential if approvals occur.
• A 20% CAGR analysts project from 2023 to 2025, driven by regulatory validation and clinical data.
• Competition from established tracers limits near-term revenue but long-term adoption hinges on clinical outcomes and manufacturing scalability.
• Market growth prospects are contingent on overcoming regulatory hurdles and demonstrating clinical superiority.

---

FAQs

1. When is Copper Cu-64 DOTATATE expected to receive FDA approval?
   No definitive timeline exists; approval depends on ongoing trial results and regulatory review timelines.

2. How does Copper Cu-64 compare to Gallium-68 in imaging performance?
   Copper-64 offers a longer half-life (12.7 hours vs. 68 minutes), enabling delayed imaging and transport flexibility, but clinical validation remains pending.

3. What are the main supply chain challenges for Copper Cu-64?
   Producing copper-64 requires reactors or cyclotrons with specific yield limitations, affecting scalability and cost.

4. Who are the leading companies involved in Copper Cu-64 DOTATATE development?
   Small biotech firms and divisions of larger pharmaceutical companies, including Curium, have shown interest, but specific market leaders are not yet established.

5. What clinical indications could broaden Copper Cu-64's market?
   Beyond neuroendocrine tumors, potential exists for imaging other receptor-expressing cancers, pending clinical validation.

---

References

[1] 2023 Market Analysis Report, Radiopharmaceuticals, MarketsandMarkets.
[2] ClinicalTrials.gov. "Copper Cu-64 DOTATATE Trials."
[3] FDA and EMA regulatory status updates.